Canakinumab - Biologic Drug Details

Summary for canakinumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for canakinumab

Recent Clinical Trials for canakinumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Shenyang Northern Hospital	PHASE4
National Institutes of Health (NIH)	PHASE2
Massachusetts General Hospital	PHASE2

See all canakinumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for canakinumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for canakinumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	7,446,175	2021-08-20	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	Injection	125319	7,446,175	2021-08-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for canakinumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,000,565	2033-11-14	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,016,338	2036-12-20	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,040,859	2035-04-21	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,041,044	2037-07-28	Patent claims search
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	10,111,968	2036-08-10	Patent claims search

Canakinumab Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market size and growth outlook for canakinumab?

Canakinumab, marketed as Ilaris, is a monoclonal antibody targeting interleukin-1β, approved for rare inflammatory and autoinflammatory conditions. The global biologic drugs market was valued at approximately $370 billion in 2022, with targeted therapies representing a significant segment. Canakinumab's market share remains limited but has potential for growth driven by expanding indications.

Forecasts project the biologics segment will grow at a CAGR of 9-12% through 2027, with specialty drugs like canakinumab benefiting from increased demand for targeted immunotherapy. The orphan drug designation lends exclusivity for certain conditions, extending market longevity and revenue streams.

How does canakinumab's regulatory status influence its commercial prospects?

Canakinumab received FDA approval in 2009 for Cryopyrin-Associated Periodic Syndromes (CAPS) and subsequent approvals for other indications, including systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease. The European Medicines Agency (EMA) granted approval in 2009 for similar indications.

The drug's orphan status confers market exclusivity until 2029 in the U.S. and 2030 in the EU for specific indications, reducing direct competition. However, evolving regulatory landscapes and potential biosimilar entries post-expiry require monitoring.

What is the revenue history and future forecast for canakinumab?

In 2022, reported global sales of canakinumab reached approximately $600 million, with the majority generated in North America and Europe. Sales plateaued between 2020-2022, influenced by generic competition for some indications and pricing pressures.

Forecasts estimate a compound annual growth rate (CAGR) of 4-6% over the next five years, driven primarily by expanding indications and increased adoption in research settings. Enrolment in ongoing clinical trials for cardiovascular and oncology indications could broaden the drug's revenue base, contingent on positive trial outcomes.

Which competitive factors impact canakinumab’s market performance?

The competitive landscape comprises other interleukin inhibitors like anakinra, rilonacept, and emerging biosimilars. Price reductions due to biosimilar competition could reduce revenue, with some estimates projecting a 20-30% decline in sales post-biologic patent expiry.

Manufacturers’ investment in novel formulations, combination therapies, or next-generation IL-1β inhibitors influences market share. Additionally, the availability of alternative treatment modalities impacts prescribing patterns.

How do pricing and reimbursement policies affect canakinumab?

Pricing varies globally, with list prices for annual treatment running between $100,000 and $150,000. Payer negotiations, especially in the US, often lead to discounts and value-based agreements. Reimbursement policies significantly influence patient access, particularly in countries with strict health technology assessment frameworks.

In the U.S., Medicaid and Medicare coverage support access, but high costs cap patient populations in some regions. The drug’s orphan status facilitates favorable reimbursement terms but does not eliminate access barriers.

What are the key R&D trends and pipeline prospects?

Research continues on canakinumab for cardiovascular risk reduction, after the CANTOS trial linked inflammation reduction to lowered cardiovascular events. Positive data could lead to broader evidence-based indications, driving sales.

Moreover, an expanding pipeline includes trials in gout, COVID-19 related cytokine storm, and certain cancers. Successful outcomes could modify the drug's financial trajectory substantially.

What are the risks and opportunities shaping the market?

Risks include biosimilar competition, pricing pressures, and regulatory delays in expanding indications. Negative clinical trial results in new indications could limit growth.

Opportunities include leveraging existing orphan drug status to expand into new rare disease niches, and adopting personalized medicine strategies to improve treatment outcomes.

Key Takeaways

• Canakinumab's market is constrained but benefits from orphan exclusivity and ongoing clinical research.
• Revenue peaked near $600 million in 2022, with moderate growth expected through 2027.
• Competition from biosimilars and alternative therapies presents ongoing threats.
• Pricing, reimbursement policies, and regulatory changes significantly influence market prospects.
• Expanding indications and positive trial results could alter the revenue trajectory.

FAQs

1. What are the main indications for canakinumab?
Cryopyrin-Associated Periodic Syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and adult-onset Still's disease.

2. When do patent expiries threaten exclusive canakinumab sales?
In the U.S., patent protections expire in 2029; in the EU, in 2030.

3. Is canakinumab being explored for cardiovascular therapy?
Yes. The CANTOS trial demonstrated reduced cardiovascular events, prompting further research.

4. Are biosimilars available for canakinumab?
As of now, no biosimilars are marketed, but imminent patent expiries could change this.

5. What future indications are in clinical development?
Gout, cytokine storm (COVID-19), and certain cancers.

---

References

1. MarketsandMarkets. (2023). Biologic drugs market analysis.
2. U.S. Food and Drug Administration. (2022). Drug approval history.
3. European Medicines Agency. (2022). Summary of product characteristics.
4. Novartis. (2022). Ilaris product information.
5. Roberts, T., et al. (2022). R&D pipelines in immunology. Pharmaceutical Technology, 46(5), 14-22.